- Home
- FWRG vs PHVS Comparison
FWRG vs PHVS Comparison
Compare FWRG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- PHVS
- Stock Information
- Founded
- FWRG 1983
- PHVS 2015
- Country
- FWRG United States
- PHVS Netherlands
- Employees
- FWRG N/A
- PHVS N/A
- Industry
- FWRG Restaurants
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- PHVS Health Care
- Exchange
- FWRG Nasdaq
- PHVS Nasdaq
- Market Cap
- FWRG 1.0B
- PHVS 1.0B
- IPO Year
- FWRG 2021
- PHVS 2021
- Fundamental
- Price
- FWRG $17.44
- PHVS $20.41
- Analyst Decision
- FWRG Strong Buy
- PHVS Buy
- Analyst Count
- FWRG 10
- PHVS 6
- Target Price
- FWRG $23.50
- PHVS $35.67
- AVG Volume (30 Days)
- FWRG 992.9K
- PHVS 60.0K
- Earning Date
- FWRG 11-07-2024
- PHVS 11-13-2024
- Dividend Yield
- FWRG N/A
- PHVS N/A
- EPS Growth
- FWRG N/A
- PHVS N/A
- EPS
- FWRG 0.33
- PHVS N/A
- Revenue
- FWRG $997,252,000.00
- PHVS N/A
- Revenue This Year
- FWRG $16.43
- PHVS N/A
- Revenue Next Year
- FWRG $15.22
- PHVS N/A
- P/E Ratio
- FWRG $52.49
- PHVS N/A
- Revenue Growth
- FWRG 19.77
- PHVS N/A
- 52 Week Low
- FWRG $12.90
- PHVS $15.37
- 52 Week High
- FWRG $25.98
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- FWRG 47.36
- PHVS 44.18
- Support Level
- FWRG $16.82
- PHVS $18.81
- Resistance Level
- FWRG $21.50
- PHVS $21.85
- Average True Range (ATR)
- FWRG 0.96
- PHVS 1.41
- MACD
- FWRG -0.33
- PHVS -0.36
- Stochastic Oscillator
- FWRG 9.83
- PHVS 23.17
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About PHVS Pharvaris N.V.
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .